US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

8.36

+0.04000.48%

Post-market: 8.360.00000.00%17:40 EDT

Volume:499.06K

Turnover:4.17M

Market Cap:454.95M

PE:-2.88

High:8.50

Open:8.31

Low:8.17

Close:8.32

52wk High:33.68

52wk Low:7.25

Shares:54.42M

Float Shares:31.42M

Volume Ratio:1.09

T/O Rate:1.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.9013

EPS(LYR):-2.6636

ROE:-41.83%

ROA:-27.76%

PB:1.50

PE(LYR):-3.14

Loading ...

Overview Company News Filings

Upstream Bio Launches $150 Million At-The-Market Program

Upstream Bio announces $150 million at-the-market equity distribution agreement with Leerink Partners

Upstream Bio Inc - Enters Sales Agreement With Leerink Partners Llc for Common Stock Offering of up to $150 Mln - SEC Filing

THOMSON REUTERS

Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors

Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster

Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug

Upstream Bio Q4 net loss widens on higher R&D costs

Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS

Upstream Bio - to Initiate Dosing in Phase 3 Trials in Both Severe Asthma and Crswnp in Q1 2027

THOMSON REUTERS

Upstream Bio Inc Q4 Net Income USD -42.459 Million

THOMSON REUTERS

Upstream Bio Inc Q4 Collaboration Revenue USD 668 Thousand

THOMSON REUTERS

Upstream Bio Inc Q4 Operating Expenses USD 46.835 Million

THOMSON REUTERS

Upstream Bio Inc expected to post a loss of 70 cents a share - Earnings Preview

Upstream Bio CEO Makes Notable Move With Fresh Stock Sale

Buy Rating on UPB Driven by Robust Verekitug Phase 2 Data and Upcoming Phase 3 Catalysts in CRSwNP and Severe Asthma

Upstream Bio announces verekitug met the primary endpoint

BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score

Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps

Upstream Bio Presents Additional Analyses From the Phase 2 Vibrant Trial of Verekitug in Chronic Rhinosinusitis With Nasal Polyps at 2026 Aaaai Annual Meeting

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/UPB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":8.36,"timestamp":1780084800000,"preClose":8.32,"halted":0,"volume":499059,"hourTrading":{"tag":"盘后","latestPrice":8.36,"preClose":8.36,"latestTime":"17:40 EDT","volume":22605,"amount":188977.8218,"timestamp":1780090856243,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004807692307692205,"floatShares":31417476,"shares":54419986,"eps":-2.901349,"marketStatus":"Market Closed","change":0.04,"latestTime":"05-29 16:00:00 EDT","open":8.31,"high":8.5,"low":8.165,"amount":4169194.7806080002,"amplitude":0.040264,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.901349,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":8.32,"postHourTrading":{"tag":"盘后","latestPrice":8.36,"preClose":8.36,"latestTime":"17:40 EDT","volume":22605,"amount":188977.8218,"timestamp":1780090856243,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0914381445161978,"impliedVol":1.1593,"impliedVolPercentile":0.6217},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":31417476,"roa":"-27.76%","roe":"-41.83%","lyrEps":-2.663615,"volumeRatio":1.0914381445161978,"shares":54419986,"dividePrice":0,"high":8.5,"amplitude":0.040264,"preClose":8.32,"low":8.165,"week52Low":7.25,"pbRate":"1.50","psRate":"136.95","week52High":33.68,"institutionHeld":0,"latestPrice":8.36,"eps":-2.901349,"divideRate":0,"volume":499059,"delay":0,"ttmEps":-2.901349,"open":8.31,"prevYearClose":27.15,"prevWeekClose":8.37,"prevMonthClose":9.18,"prevQuarterClose":9,"fiveDayClose":8.46,"twentyDayClose":9.18,"sixtyDayClose":7.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-13","symbol":"UPB","fiscalQuarterEnding":"2026/03","expectedEps":-0.8,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2026-03-26","symbol":"UPB","fiscalQuarterEnding":"2025/12","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-0.79},{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.75,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1774670400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2026-05-29","current":-2.881418,"percent":0.992629,"low":-36.237602,"twenty":-13.287802,"median":-8.694854,"eighty":-5.684399,"high":-2.787582,"avg":-10.598037,"sd":6.903649,"marketCap":452774283},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999},{"date":"2025-06-27","current":-7.432284,"twenty":-21.589777,"median":-8.421362,"eighty":-6.683973,"marketCap":588503110},{"date":"2025-07-03","current":-7.60892,"twenty":-21.547111,"median":-8.293047,"eighty":-6.875286,"marketCap":602489473},{"date":"2025-07-11","current":-8.043715,"twenty":-21.219023,"median":-8.229183,"eighty":-7.004282,"marketCap":636917443},{"date":"2025-07-18","current":-7.500221,"twenty":-20.486294,"median":-8.00983,"eighty":-7.116503,"marketCap":593882481},{"date":"2025-07-25","current":-9.06956,"twenty":-20.325696,"median":-7.964314,"eighty":-7.165671,"marketCap":718145935},{"date":"2025-08-01","current":-10.401121,"twenty":-19.703378,"median":-8.043715,"eighty":-7.186764,"marketCap":823581592},{"date":"2025-08-08","current":-8.173881,"twenty":-19.517686,"median":-8.19076,"eighty":-7.191293,"marketCap":853925323},{"date":"2025-08-15","current":-9.608438,"twenty":-19.472518,"median":-8.256445,"eighty":-7.228474,"marketCap":1003793530},{"date":"2025-08-22","current":-9.154334,"twenty":-19.472518,"median":-8.332111,"eighty":-7.228474,"marketCap":956353234},{"date":"2025-08-29","current":-8.648626,"twenty":-19.29215,"median":-8.429698,"eighty":-7.242061,"marketCap":903521996},{"date":"2025-09-05","current":-10.155428,"twenty":-19.267816,"median":-8.442215,"eighty":-7.274671,"marketCap":1060937523},{"date":"2025-09-12","current":-9.247219,"twenty":-19.117195,"median":-8.531282,"eighty":-7.282823,"marketCap":966056931},{"date":"2025-09-19","current":-8.911801,"twenty":-19.040911,"median":-8.561886,"eighty":-7.298422,"marketCap":931015804},{"date":"2025-09-26","current":-8.416414,"twenty":-18.814066,"median":-8.561394,"eighty":-7.303028,"marketCap":879262754},{"date":"2025-10-03","current":-9.592957,"twenty":-18.486847,"median":-8.591998,"eighty":-7.324944,"marketCap":1002176247},{"date":"2025-10-10","current":-10.212191,"twenty":-18.290115,"median":-8.630565,"eighty":-7.351996,"marketCap":1066867560},{"date":"2025-10-17","current":-11.4971,"twenty":-18.113457,"median":-8.648626,"eighty":-7.357523,"marketCap":1201102033},{"date":"2025-10-24","current":-10.903668,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"marketCap":1139106192},{"date":"2025-10-31","current":-13.298037,"twenty":-17.320504,"median":-8.903157,"eighty":-7.366819,"marketCap":1389245933},{"date":"2025-11-07","current":-10.460565,"twenty":-17.071577,"median":-8.919541,"eighty":-7.375835,"marketCap":1278553063},{"date":"2025-11-14","current":-10.319087,"twenty":-16.746366,"median":-8.953083,"eighty":-7.3842,"marketCap":1261260713},{"date":"2025-11-21","current":-11.035322,"twenty":-16.535581,"median":-9.042102,"eighty":-7.390371,"marketCap":1348803231},{"date":"2025-11-28","current":-12.644639,"twenty":-16.41714,"median":-9.068084,"eighty":-7.395598,"marketCap":1545503702},{"date":"2025-12-05","current":-12.264416,"twenty":-16.306728,"median":-9.154334,"eighty":-7.402392,"marketCap":1499030514},{"date":"2025-12-12","current":-12.145044,"twenty":-16.258549,"median":-9.253501,"eighty":-7.413262,"marketCap":1484440094},{"date":"2025-12-19","current":-13.201711,"twenty":-16.238474,"median":-9.412348,"eighty":-7.419454,"marketCap":1613592327},{"date":"2025-12-26","current":-13.38298,"twenty":-16.206354,"median":-9.577476,"eighty":-7.422171,"marketCap":1635748149},{"date":"2026-01-02","current":-12.003565,"twenty":-15.686418,"median":-9.608438,"eighty":-7.426849,"marketCap":1467147745},{"date":"2026-01-09","current":-12.175992,"twenty":-13.691713,"median":-9.623919,"eighty":-7.437719,"marketCap":1488222796},{"date":"2026-01-16","current":-13.661516,"twenty":-14.223893,"median":-9.706483,"eighty":-7.459459,"marketCap":1669792461},{"date":"2026-01-23","current":-14.055003,"twenty":-14.055003,"median":-9.763246,"eighty":-7.459459,"marketCap":1717886807},{"date":"2026-01-30","current":-13.679201,"twenty":-14.055003,"median":-9.837934,"eighty":-7.487886,"marketCap":1671954005},{"date":"2026-02-06","current":-11.495127,"twenty":-13.997527,"median":-9.967119,"eighty":-7.498759,"marketCap":1405003366},{"date":"2026-02-13","current":-5.659139,"twenty":-13.966579,"median":-10.045793,"eighty":-7.487886,"marketCap":691693964},{"date":"2026-02-20","current":-3.775707,"twenty":-13.794285,"median":-9.921951,"eighty":-7.430925,"marketCap":461489567},{"date":"2026-02-27","current":-3.49275,"twenty":-13.743121,"median":-9.768407,"eighty":-7.40375,"marketCap":426904868},{"date":"2026-03-06","current":-3.391062,"twenty":-13.712802,"median":-9.724309,"eighty":-7.375835,"marketCap":414475992},{"date":"2026-03-13","current":-4.171405,"twenty":-13.705728,"median":-9.63424,"eighty":-7.351996,"marketCap":509854106},{"date":"2026-03-20","current":-3.704968,"twenty":-13.684506,"median":-9.611018,"eighty":-7.282823,"marketCap":452843392},{"date":"2026-03-27","current":-3.71417,"twenty":-13.665053,"median":-9.577476,"eighty":-7.221038,"marketCap":532771662},{"date":"2026-04-02","current":-3.532065,"twenty":-13.632336,"median":-9.412348,"eighty":-7.146004,"marketCap":506650069},{"date":"2026-04-10","current":-3.953182,"twenty":-13.517385,"median":-9.253501,"eighty":-6.612231,"marketCap":567056254},{"date":"2026-04-17","current":-3.831779,"twenty":-13.45372,"median":-9.154334,"eighty":-6.50272,"marketCap":549641858},{"date":"2026-04-24","current":-3.642087,"twenty":-13.411276,"median":-9.068084,"eighty":-6.341219,"marketCap":522431865},{"date":"2026-05-01","current":-3.482746,"twenty":-13.38298,"median":-9.030487,"eighty":-6.247466,"marketCap":499575471},{"date":"2026-05-08","current":-3.408766,"twenty":-13.356783,"median":-8.950503,"eighty":-6.042298,"marketCap":488963574},{"date":"2026-05-15","current":-3.051413,"twenty":-13.336336,"median":-8.911801,"eighty":-5.873814,"marketCap":478351676},{"date":"2026-05-22","current":-2.936855,"twenty":-13.312561,"median":-8.871357,"eighty":-5.82388,"marketCap":460393081},{"date":"2026-05-29","current":-2.888254,"twenty":-13.287802,"median":-8.694854,"eighty":-5.684399,"marketCap":452774283}],"updateTime":1780228587764},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622689451","title":"Upstream Bio Launches $150 Million At-The-Market Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622689451?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:30","pubTimestamp":1774560616,"startTime":"0","endTime":"0","summary":"Upstream Bio, Inc. ( ($UPB) ) has issued an update. On March 26, 2026, Upstream Bio, Inc. entered into a sales agreement with Leerink Partners LLC ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/upstream-bio-launches-150-million-at-the-market-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/upstream-bio-launches-150-million-at-the-market-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622193891","title":"Upstream Bio announces $150 million at-the-market equity distribution agreement with Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2622193891","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622193891?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:10","pubTimestamp":1774559409,"startTime":"0","endTime":"0","summary":"Upstream Bio entered into an at-the-market equity distribution agreement with Leerink Partners as sales agent for sales of common stock.The program allows sales of up to USD 150.0 million of shares from time to time through or to the agent.Leerink Partners is entitled to a commission of up to 3% of gross proceeds on shares sold under the agreement.Sales may be made on Nasdaq or other existing trading markets for the common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2MPsh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","UPB","BK4139","MNSH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622919638","title":"Upstream Bio Inc - Enters Sales Agreement With Leerink Partners Llc for Common Stock Offering of up to $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622919638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622919638?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:06","pubTimestamp":1774559217,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0ZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622898676","title":"Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898676","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622898676?lang=en_us&edition=fundamental","pubTime":"2026-03-27 01:45","pubTimestamp":1774547119,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today. Matt Phipps has given his Buy rating...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-initiated-at-buy-verekitugs-quarterly-dosing-strategy-positions-it-for-potential-best-in-class-efficacy-vs-tslp-competitors-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-initiated-at-buy-verekitugs-quarterly-dosing-strategy-positions-it-for-potential-best-in-class-efficacy-vs-tslp-competitors-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622867477","title":"Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster","url":"https://stock-news.laohu8.com/highlight/detail?id=2622867477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622867477?lang=en_us&edition=fundamental","pubTime":"2026-03-27 00:45","pubTimestamp":1774543520,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today. Yaron Werber has given his Buy rating du...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/verekitugs-differentiated-long-interval-dosing-and-late-stage-pipeline-position-it-as-a-potential-respiratory-blockbuster-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/verekitugs-differentiated-long-interval-dosing-and-late-stage-pipeline-position-it-as-a-potential-respiratory-blockbuster-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622586254","title":"Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug","url":"https://stock-news.laohu8.com/highlight/detail?id=2622586254","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622586254?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:45","pubTimestamp":1774539917,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Kate Dellorusso has maintained their bullish stance on UPB stock, giving a Buy rating on March 11. Kate Dellorusso has give...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-backed-by-valiant-phase-2-asthma-data-and-differentiated-infrequent-dosing-profile-for-verekitug-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-backed-by-valiant-phase-2-asthma-data-and-differentiated-infrequent-dosing-profile-for-verekitug-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622785118","title":"Upstream Bio Q4 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2622785118","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622785118?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:07","pubTimestamp":1774523256,"startTime":"0","endTime":"0","summary":"Upstream Bio Q4 net loss widens on higher R&D costsOverviewUS biotech firm's Q4 collaboration revenue was modest, net loss widened due to higher R&D costsCompany expects cash of $341.5 mln to fund ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL1N40E0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851551","title":"Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851551","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851551?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:02","pubTimestamp":1774522954,"startTime":"0","endTime":"0","summary":"Upstream Bio published a press release reporting fourth-quarter and full-year 2025 financial results and outlining its Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps.Cash, cash equivalents and short-term investments totaled USD 341.5 million as of Dec. 31, 2025, with the company expecting this to fund planned operations through 2027.Research and development expenses rose 84.46% to USD 40.2 million for the quarter, driven primarily by higher clinical and manufacturing expenses for verekitug programs.Net loss widened 99.86% to USD 42.5 million for the quarter.Management said it plans to initiate dosing in Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, following positive Phase 2 results and planned FDA engagement later this year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8rp4hV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","IE00B3QW5Z07.USD","UPB","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622985186","title":"Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622985186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622985186?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUANTPXL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851512","title":"Upstream Bio - to Initiate Dosing in Phase 3 Trials in Both Severe Asthma and Crswnp in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851512?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUANTPXL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622885182","title":"Upstream Bio Inc Q4 Net Income USD -42.459 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622885182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622885182?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLXADA2DD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851334","title":"Upstream Bio Inc Q4 Collaboration Revenue USD 668 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851334?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLXADA2DD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622318851","title":"Upstream Bio Inc Q4 Operating Expenses USD 46.835 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622318851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622318851?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLXADA2DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739596","title":"Upstream Bio Inc  expected to post a loss of 70 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739596","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739596?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:04","pubTimestamp":1774011846,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc  expected to post a loss of70cents a share - Earnings Preview Upstream Bio Inc UPB.OQ UPB.O is expected to  show a fall in quarterly revenue when it reports  results on March 23 (esti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40819V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620288414","title":"Upstream Bio CEO Makes Notable Move With Fresh Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2620288414","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620288414?lang=en_us&edition=fundamental","pubTime":"2026-03-18 10:09","pubTimestamp":1773799743,"startTime":"0","endTime":"0","summary":"New insider activity at Upstream Bio, Inc. ( ($UPB) ) has taken place on March 17, 2026. Upstream Bio, Inc. has reported insider selling activity b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/upstream-bio-ceo-makes-notable-move-with-fresh-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/upstream-bio-ceo-makes-notable-move-with-fresh-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616340040","title":"Buy Rating on UPB Driven by Robust Verekitug Phase 2 Data and Upcoming Phase 3 Catalysts in CRSwNP and Severe Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340040","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340040?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:55","pubTimestamp":1772542554,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Tessa Romero has maintained their bullish stance on UPB stock, giving a Buy rating yesterday. Tessa Romero has given his Buy ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-upb-driven-by-robust-verekitug-phase-2-data-and-upcoming-phase-3-catalysts-in-crswnp-and-severe-asthma-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-upb-driven-by-robust-verekitug-phase-2-data-and-upcoming-phase-3-catalysts-in-crswnp-and-severe-asthma-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616878069","title":"Upstream Bio announces verekitug met the primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2616878069","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616878069?lang=en_us&edition=fundamental","pubTime":"2026-03-02 00:35","pubTimestamp":1772382925,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) presented additional data from the Phase 2 Vibrant clinical trial evaluating verekitug in participants with chronic rhinosinusit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-announces-verekitug-met-the-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-announces-verekitug-met-the-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616782016","title":"BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score","url":"https://stock-news.laohu8.com/highlight/detail?id=2616782016","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616782016?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:47","pubTimestamp":1772376426,"startTime":"0","endTime":"0","summary":"BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp ScoreMarch 1 (Reuters) - Upstream Bio Inc UPB.O:UPSTREAM BIO PRESENTS ADDITIONAL ANALYSES FROM THE PHASE 2 VIBRANT TRI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUABNVLKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616201618","title":"Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2616201618","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616201618?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376320,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. reported additional analyses from its Phase 2 VIBRANT trial  evaluating verekitug in 81 adults with chronic rhinosinusitis with nasal polyps over 24 weeks. The new analyses adjusted for concomitant rescue therapy use using a worst-observation carried-forward approach and showed a placebo-adjusted reduction in endoscopic nasal polyp score of -1.95  and a reduction in nasal congestion score of -0.96  at week 24; the company also reiterated previously reported data showing a 76% reduction in the need for surgery or systemic corticosteroids versus placebo . These additional results were presented at the AAAAI 2026 Annual Meeting, and the company said planning has begun for Phase 3 trials in chronic rhinosinusitis with nasal polyps and severe asthma.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nNDL3YqRrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU0314104364.USD","SG9999014039.USD","BK4585","BK4588","BK4139","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4112","UPB","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616820978","title":"Upstream Bio Presents Additional Analyses From the Phase 2 Vibrant Trial of Verekitug in Chronic Rhinosinusitis With Nasal Polyps at 2026 Aaaai Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2616820978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616820978?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUABNVLKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":66,"code":"91000000","status":"200"}]}}